Cargando…

A Review of Nutraceuticals in Cancer Cachexia

SIMPLE SUMMARY: Cancer-related muscle wasting and inflammation, known as cachexia, leads to weight loss and worsened physical function, quality of life (QOL), and survival. The main barrier to current treatments is the lack of improvement in clinically relevant outcomes (function, QOL). Nutraceutica...

Descripción completa

Detalles Bibliográficos
Autores principales: Caeiro, Lucas, Gandhay, Devika, Anderson, Lindsey J., Garcia, Jose M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10417577/
https://www.ncbi.nlm.nih.gov/pubmed/37568700
http://dx.doi.org/10.3390/cancers15153884
_version_ 1785088071025295360
author Caeiro, Lucas
Gandhay, Devika
Anderson, Lindsey J.
Garcia, Jose M.
author_facet Caeiro, Lucas
Gandhay, Devika
Anderson, Lindsey J.
Garcia, Jose M.
author_sort Caeiro, Lucas
collection PubMed
description SIMPLE SUMMARY: Cancer-related muscle wasting and inflammation, known as cachexia, leads to weight loss and worsened physical function, quality of life (QOL), and survival. The main barrier to current treatments is the lack of improvement in clinically relevant outcomes (function, QOL). Nutraceuticals are naturally occurring food products, which may be of benefit in cancer cachexia. This review describes the effect of nutraceuticals in animal models and in clinical trials in patients with cancer cachexia. Human studies mostly tested fish oil (or something similar) or amino acids (the building blocks of proteins). Body weight was the main focus, while some also assessed muscle mass and QOL, and very few measured physical function. The safety and efficacy of nutraceuticals in treating cancer-related muscle wasting remains uncertain. More animal and large human studies are needed, and they should focus on clinically meaningful outcomes, such as physical function and QOL. ABSTRACT: Cancer cachexia is largely characterized by muscle wasting and inflammation, leading to weight loss, functional impairment, poor quality of life (QOL), and reduced survival. The main barrier to therapeutic development is a lack of efficacy for improving clinically relevant outcomes, such as physical function or QOL, yet most nutraceutical studies focus on body weight. This review describes clinical and pre-clinical nutraceutical studies outside the context of complex nutritional and/or multimodal interventions, in the setting of cancer cachexia, in view of considerations for future clinical trial design. Clinical studies mostly utilized polyunsaturated fatty acids or amino acids/derivatives, and they primarily focused on body weight and, secondarily, on muscle mass and/or QOL. The few studies that measured physical function almost exclusively utilized handgrip strength with, predominantly, no time and/or group effect. Preclinical studies focused mainly on amino acids/derivatives and polyphenols, assessing body weight, muscle mass, and occasionally physical function. While this review does not provide sufficient evidence of the efficacy of nutraceuticals for cancer cachexia, more preclinical and adequately powered clinical studies are needed, and they should focus on clinically meaningful outcomes, including physical function and QOL.
format Online
Article
Text
id pubmed-10417577
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-104175772023-08-12 A Review of Nutraceuticals in Cancer Cachexia Caeiro, Lucas Gandhay, Devika Anderson, Lindsey J. Garcia, Jose M. Cancers (Basel) Review SIMPLE SUMMARY: Cancer-related muscle wasting and inflammation, known as cachexia, leads to weight loss and worsened physical function, quality of life (QOL), and survival. The main barrier to current treatments is the lack of improvement in clinically relevant outcomes (function, QOL). Nutraceuticals are naturally occurring food products, which may be of benefit in cancer cachexia. This review describes the effect of nutraceuticals in animal models and in clinical trials in patients with cancer cachexia. Human studies mostly tested fish oil (or something similar) or amino acids (the building blocks of proteins). Body weight was the main focus, while some also assessed muscle mass and QOL, and very few measured physical function. The safety and efficacy of nutraceuticals in treating cancer-related muscle wasting remains uncertain. More animal and large human studies are needed, and they should focus on clinically meaningful outcomes, such as physical function and QOL. ABSTRACT: Cancer cachexia is largely characterized by muscle wasting and inflammation, leading to weight loss, functional impairment, poor quality of life (QOL), and reduced survival. The main barrier to therapeutic development is a lack of efficacy for improving clinically relevant outcomes, such as physical function or QOL, yet most nutraceutical studies focus on body weight. This review describes clinical and pre-clinical nutraceutical studies outside the context of complex nutritional and/or multimodal interventions, in the setting of cancer cachexia, in view of considerations for future clinical trial design. Clinical studies mostly utilized polyunsaturated fatty acids or amino acids/derivatives, and they primarily focused on body weight and, secondarily, on muscle mass and/or QOL. The few studies that measured physical function almost exclusively utilized handgrip strength with, predominantly, no time and/or group effect. Preclinical studies focused mainly on amino acids/derivatives and polyphenols, assessing body weight, muscle mass, and occasionally physical function. While this review does not provide sufficient evidence of the efficacy of nutraceuticals for cancer cachexia, more preclinical and adequately powered clinical studies are needed, and they should focus on clinically meaningful outcomes, including physical function and QOL. MDPI 2023-07-30 /pmc/articles/PMC10417577/ /pubmed/37568700 http://dx.doi.org/10.3390/cancers15153884 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Caeiro, Lucas
Gandhay, Devika
Anderson, Lindsey J.
Garcia, Jose M.
A Review of Nutraceuticals in Cancer Cachexia
title A Review of Nutraceuticals in Cancer Cachexia
title_full A Review of Nutraceuticals in Cancer Cachexia
title_fullStr A Review of Nutraceuticals in Cancer Cachexia
title_full_unstemmed A Review of Nutraceuticals in Cancer Cachexia
title_short A Review of Nutraceuticals in Cancer Cachexia
title_sort review of nutraceuticals in cancer cachexia
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10417577/
https://www.ncbi.nlm.nih.gov/pubmed/37568700
http://dx.doi.org/10.3390/cancers15153884
work_keys_str_mv AT caeirolucas areviewofnutraceuticalsincancercachexia
AT gandhaydevika areviewofnutraceuticalsincancercachexia
AT andersonlindseyj areviewofnutraceuticalsincancercachexia
AT garciajosem areviewofnutraceuticalsincancercachexia
AT caeirolucas reviewofnutraceuticalsincancercachexia
AT gandhaydevika reviewofnutraceuticalsincancercachexia
AT andersonlindseyj reviewofnutraceuticalsincancercachexia
AT garciajosem reviewofnutraceuticalsincancercachexia